Tj Biopharma Co., Ltd.

This study tests whether adding a new drug called uliledlimab to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer live longer without their disease getting worse. About 150 adults who have not had prior treatment for their advanced …

This study tests whether a new drug combination (uliledlimab plus toripalimab) works better than the standard immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that hasn't been treated yet. The trial includes 450 participants whose tumors have specif…